A triple-agonist peptide molecule engineered for concurrent activation of three separate receptor systems: GIP, GLP-1, and glucagon receptors. Represents a more complex pharmacological approach, integrating multiple metabolic regulatory pathways into a single molecular entity. The compound’s tripartite mechanism enables modulation of insulin secretion, energy expenditure, and lipid metabolism through coordinated receptor activation, exhibiting broader metabolic impact than dual-agonist predecessors.